NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

Johanna Hilli (1, 2) , Liisa Sailas (3) , Sirkku Jyrkkiö (4) , Seppo Pyrhönen (4) , Kari Laine (1, 2, 5)

1 Department of Pharmacology, Drug Development and Therapeutics
2 Unit of Clinical Pharmacology
3 Department of Oncology
4 Department of Oncology and Radiotherapy
5 medbase Oy Ltd

Mots clés: Docetaxel; CYP3A activity; Peroral midazolam; Dexamethasone; Induction

Johanna Hilli, Liisa Sailas, Sirkku Jyrkkiö, Seppo Pyrhönen, Kari Laine. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemotherapy and Pharmacology, 2010, 67 (6), pp.1353-1362. ⟨10.1007/s00280-010-1426-6⟩. ⟨hal-00617337⟩